论文部分内容阅读
目的探讨尿激酶联合低分子肝素治疗急性心肌梗死的临床疗效。方法选取2010年8月至2011年8月收治的急性心肌梗死患者94例,随机分为研究组和对照组。两组均行常规治疗,而研究组则加用尿激酶与低分子肝素联合治疗。结果研究组与对照组相比,显效率和总有效率均显著提高,无效率显著降低,差异均具有统计学意义(P<0.05)。讨论尿激酶联合低分子肝素治疗急性心肌梗死具有较好的有效性和安全性,值得进一步的临床推广和应用。
Objective To investigate the clinical efficacy of urokinase combined with low molecular weight heparin in the treatment of acute myocardial infarction. Methods 94 patients with acute myocardial infarction admitted from August 2010 to August 2011 were randomly divided into study group and control group. Both groups were treated routinely, while the study group was treated with urokinase combined with low molecular weight heparin. Results Compared with the control group, both the markedly effective rate and the total effective rate were significantly increased in the study group and the inefficiency was significantly reduced, with statistical significance (P <0.05). Discussion Urokinase combined with low molecular weight heparin in the treatment of acute myocardial infarction has good efficacy and safety, it is worth further clinical promotion and application.